Adagene (FRA:978) Gross-Profit-to-Asset % : 0.22% (As of Dec. 2024)

View and export this data going back to 2021. Start your Free Trial

What is Adagene Gross-Profit-to-Asset %?

Gross-Profit-to-Asset % is calculated as Gross Profit divided by its average Total Assets over a certain period of time. Adagene's annualized Gross Profit for the quarter that ended in Dec. 2024 was €0.20 Mil. Adagene's average Total Assets over the quarter that ended in Dec. 2024 was €89.44 Mil. Therefore, Adagene's annualized Gross-Profit-to-Asset % for the quarter that ended in Dec. 2024 was 0.22%.

Adagene Gross-Profit-to-Asset % Historical Data

The historical data trend for Adagene's Gross-Profit-to-Asset % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Adagene Gross-Profit-to-Asset % Chart

Adagene Annual Data

Trend

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

Dec24

Gross-Profit-to-Asset %

Get a 7-Day Free Trial

0.70

7.60

5.63

13.29

0.10

Adagene Semi-Annual Data
	Dec18	Dec19	Jun20	Dec20	Jun21	Dec21	Jun22	Dec22	Jun23	Dec23	Jun24	Dec24
Gross-Profit-to-Asset %	Get a 7-Day Free Trial							6.48	23.76	1.30	-	0.22

Competitive Comparison of Adagene's Gross-Profit-to-Asset %

For the Biotechnology subindustry, Adagene's Gross-Profit-to-Asset %, along with its competitors' market caps and Gross-Profit-to-Asset % data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Adagene's Gross-Profit-to-Asset % Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Adagene's Gross-Profit-to-Asset % distribution charts can be found below:

* The bar in red indicates where Adagene's Gross-Profit-to-Asset % falls into.

Save Embed

;

Save Embed

;

Adagene Gross-Profit-to-Asset % Calculation

Adagene's annualized Gross-Profit-to-Asset % for the fiscal year that ended in Dec. 2024 is calculated as:

Gross-Profit-to-Asset %	=	Gross Profit (A: Dec. 2024 )	/	( (Total Assets (A: Dec. 2023 )	+	Total Assets (A: Dec. 2024 ))	/ count )
	=	0.098	/	( (106.123	+	85.251)	/ 2 )
	=	0.098	/	95.687
	=	0.10 %

Adagene's annualized Gross-Profit-to-Asset % for the quarter that ended in Dec. 2024 is calculated as:

Gross-Profit-to-Asset %	=	Gross Profit (Q: Dec. 2024 )	/	( (Total Assets (Q: Jun. 2024 )	+	Total Assets (Q: Dec. 2024 ))	/ count )
	=	0.196	/	( (93.625	+	85.251)	/ 2 )
	=	0.196	/	89.438
	=	0.22 %

In the calculation of annual Gross-Profit-to-Asset %, the Gross Profit of the last fiscal year and the average total assets over the fiscal year are used. In calculating the quarterly data, the Gross Profit data used here is two times the semi-annual (Dec. 2024) data. Gross-Profit-to-Asset % is displayed in the 30-year financial page.

Adagene Gross-Profit-to-Asset % Related Terms

Thank you for viewing the detailed overview of Adagene's Gross-Profit-to-Asset % provided by GuruFocus.com. Please click on the following links to see related term pages.

Adagene Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Adagene Inc (FRA:978) » Definitions » Gross-Profit-to-Asset %

Comparable Companies

Traded in Other Exchanges

ADAG:USA 978:Germany

Address

Xinghu Street, Suzhou Industrial Park, 4th Floor, Building C14, No. 218, Jiangsu Province, Suzhou, CHN, 215123

Website

https://www.adagene.com

Adagene Inc is a platform-driven, clinical-stage biopharmaceutical company engaged in transforming the discovery and development of novel antibody-based cancer immunotherapies. It is principally engaged in research, development, and production of monoclonal antibody drugs for cancers. The company's platform is designed to generate therapeutic antibody candidates with functional epitopes and species cross-reactivity, as highlighted by the company's immunotherapy pipeline.

Adagene Headlines

No Headlines